Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?
By the Top Tier Newswire AI Desk · September 18, 2026 at 12:10 AM ET · reviewed against 12 wire stories
ULTRAGENYX PHARMACEU (RARE) is up +12.58% in the latest session. Our newswire has captured 12 stories on RARE across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RARE stock is up today
Ultragenyx Pharmaceutical Inc (RARE) surged 12.58% to $14.50 in early trading after the U.S. Food and Drug Administration granted full approval for FAYUVI, the first gene therapy for children with Sanfilippo syndrome type A. The approval marks a significant milestone for the company and is expected to drive long-term growth. The drug is now positioned for a 30- to 60-day launch period.
What Happened
The FDA’s full approval of FAYUVI represents the first treatment for Sanfilippo syndrome type A, a rare and devastating pediatric condition. The therapy is designed to slow or stop the irreversible neurological progression associated with the disease. The approval was announced in a Form 8-K filing on September 17 and has been widely reported across multiple financial and medical news outlets. In addition to the regulatory win, Ultragenyx stands to collect mid-single-digit royalties on sales of FAYUVI and is eligible for up to $30 million in commercial milestone payments under a licensing agreement with Abeona Therapeutics.
What The Data Shows
The stock has been volatile over the past 52 weeks, trading between $12.73 and $39.89. Over the last eight sessions, it had fallen 8.1% from $14.82 to $13.61. The recent approval has reversed that trend. The company remains unprofitable, with a trailing twelve-month EPS of -5.83 and a net margin of -81.7%. Revenue, however, grew 17.5% in the same period. The stock has also seen unusual price action, with 21 fresh 52-week highs and 2 lows recorded on the day of approval.
What To Watch
Ultragenyx has not announced an upcoming earnings date. Investors should monitor the breadth of analyst coverage and any new developments regarding FAYUVI’s commercial launch.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 12 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
9h agoStocktwits NewsBULLISH 63General
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
10h agoReutersBEARISH 28General
Ultragenyx sets $3.95 million price for rare disease gene therapy
10h agoTechStock²BULLISH 73Product/PR
FAYUVI Wins Full FDA Approval; Ultragenyx Stock Adds 12.6% Before a 30–60 Day Launch
Ultragenyx Pharmaceutical shares advanced 12.6% Thursday after the U.S. Food and Drug Administration granted full approval to FAYUVI, the first approved treatment for children with Sanfilippo syndrome type A. The decision removes the main regulatory risk, but the commercial test will not begin immediately: Ultragenyx expects to ship the one-time gene therapy to qualified treatment…
12h agoTipRanksBULLISH 78Product/PR
Ultragenyx wins FDA approval for FAYUVI gene therapy
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A
13h agoSeeking AlphaBULLISH 78Product/PR
Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
FDA approves Ultragenyx’s Fayuvi, first pediatric gene therapy for Sanfilippo A targeting root cause. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →